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INTRODUCTION
Glaucoma is a neurodegenerative disease of the eye and is 
one of the leading causes of visual impairment and blind-
ness, affecting more than 60 million individuals worldwide.1 
Primary open-angle glaucoma (POAG; OMIM 137760), the 
most common form of glaucoma, is defined as a spectrum 
of diseases causing vision loss as a result of progressive and 
irreversible retinal ganglion cell (RGC) damage, optic nerve 
degeneration, and corresponding visual field loss.2 POAG is 
usually associated with elevated intraocular pressure (IOP), 
and this subtype is termed high-tension glaucoma, defined 
as an IOP >21 mm Hg with a clinically open anterior cham-
ber drainage angle.2 POAG accounts for 9–12% of all cases of 
blindness in the United States.3
Glaucoma is characterized by the slow, progressive degen-
eration of RGCs associated with structural changes at the optic 
nerve head in the form of pathological cupping and visual field 
loss.2,4 The preferential loss of RGCs in glaucoma is also a key 
pathological feature seen in Leber hereditary optic neuropathy 
and autosomal dominant optic atrophy.5,6 Mitochondrial abnor-
malities are associated with a number of optic neuropathies,5,6 
and there is evidence that mitochondrial DNA (mtDNA) 
defects and dysfunction play a role in POAG.7–12 Mitochondrial 
genetic variants have also been linked to other neurodegenera-
tive diseases, including Parkinson disease, Alzheimer disease, 
and Friedreich ataxia.13
The mitochondrial genome is organized as a circular, double-
stranded DNA molecule in the mitochondrion and codes for 
only 37 genes across ~16,600 base pairs.14 mtDNA can rep-
licate independently of nuclear DNA, and in humans there 
are usually 100–10,000 separate copies of mtDNA present in 
each cell. Mitochondrial mutations can be inherited through 
the maternal line or acquired throughout life (somatic muta-
tions). Somatic mutations accumulate more frequently in the 
mitochondrial genome, which lacks the protective histones 
and efficient DNA repair system associated with the nuclear 
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Purpose: The aim of this study was to determine whether mutations 
in mitochondrial DNA play a role in high-pressure primary open-
angle glaucoma (OMIM 137760) by analyzing new data from mas-
sively parallel sequencing of mitochondrial DNA.
Methods: Glaucoma patients with high-tension primary open-angle 
glaucoma and ethnically matched and age-matched control subjects 
without glaucoma were recruited. The entire human mitochondrial 
genome was amplified in two overlapping fragments by long-range 
polymerase chain reaction and used as a template for massively par-
allel sequencing on an Ion Torrent Personal Genome Machine. All 
variants were confirmed by conventional Sanger sequencing.
Results: Whole-mitochondrial genome sequencing was performed 
in 32 patients with primary open-angle glaucoma from India (n = 16) 
and Ireland (n = 16). In 16 of the 32 patients with primary open-
angle glaucoma (50% of cases), there were 22 mitochondrial DNA 
mutations consisting of 7 novel mutations and 8 previously reported 
disease-associated sequence variants. Eight of 22 (36.4%) of the mito-
chondrial DNA mutations were in complex I mitochondrial genes.
Conclusion: Massively parallel sequencing using the Ion Torrent 
Personal Genome Machine with confirmation by Sanger sequenc-
ing detected a pathogenic mitochondrial DNA mutation in 50% 
of the primary open-angle glaucoma cohort. Our findings support 
the emerging concept that mitochondrial dysfunction results in the 
development of glaucoma and, more specifically, that complex I 
defects play a significant role in primary open-angle glaucoma patho-
genesis.
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genome.14,15 Mitochondria may contribute to their own accel-
erated DNA mutational rate during periods of localized envi-
ronmental stress; mitochondria both generate and act as 
a target for excessive reactive oxygen species from altered 
 oxidative  phosphorylation.9 Several mtDNA variants can exist 
within a cell or tissue, a situation termed heteroplasmy. New 
mtDNA mutations can coexist at a low frequency with wild-
type mtDNAs, making it challenging to identify all mutations 
in the  mitochondrial genome. “Massively parallel” or “next-
generation” sequencing approaches have ushered in a new era 
of opportunity in mtDNA mutation analysis,16,17 enhancing 
understanding of mtDNA-based disorders.18 Massively parallel 
sequencing can characterize the complete nucleotide sequence 
for the mitochondrial genome and provide adequate sequenc-
ing depth to identify heteroplasmic positions with enhanced 
sensitivity and estimate the mutant load at each nucleotide posi-
tion. The aim of this study was to determine whether mutations 
in mtDNA play a role in POAG using massively parallel, whole-
mitochondrial genome sequencing on the Ion Torrent Personal 
Genome Machine (PGM; Life Technologies, Paisley, UK).
MATERIALS AND METHODS
Patients
Patients with high-tension POAG were recruited after careful 
phenotyping from the departments of ophthalmology in Dublin 
(Mater Misericordiae University Hospital, Dublin, Ireland) and 
Pune (PBMA’s H. V. Desai Eye Hospital, Pune,  India). Written 
informed consent was obtained from all subjects, and the study 
was performed according to the tenets of the Declaration of 
Helsinki and the guidelines of the Indian Council of Medical 
Research, New Delhi, India. All subjects underwent a standard-
ized ophthalmic examination; the clinical parameters used for 
the case definition of high-tension POAG were as follows: (i) 
presenting IOP >21 mm Hg in at least one eye by Goldmann 
applanation tonometry; (ii) glaucomatous optic nerve head 
damage on stereoscopic optic disc examination (notching or 
thinning of the neuroretinal rim and/or increased cup/disc 
ratio in relation to the optic disc size); (iii) an open anterior 
chamber angle on gonioscopy; (iv) reproducible and charac-
teristic glaucomatous visual field defect with the Humphrey 
24-2 full-threshold strategy when available (Carl Zeiss Meditec, 
Oberkochen, Germany); and (v) absence of conditions leading 
to secondary glaucoma (e.g., pigmentary dispersion syndrome, 
pseudoexfoliation, history of steroid use, uveitis, or ocular 
trauma). Ethnically matched and age-matched control subjects 
without glaucoma (based on normal IOP) were also recruited 
from each study population.
DNA Extraction and Polymerase Chain Reaction 
Amplification of Mitochondrial Genome
Genomic DNA was extracted from peripheral blood leuko-
cytes from all the subjects using a Qiagen DNA Purification 
Kit (Qiagen, Manchester, UK) according to the manu-
facturer’s instructions. The entire human mitochondrial 
genome was amplified in two overlapping fragments: 
fragment 1 (5′-AACCAAACCCCAAAGACACC-3′ and 5′-GCC 
AATAATGACGTGAAGTCC-3′; product size: 9,289 bp) and 
fragment 2 (5′-TCCCACTCCTAAACACATCC-3′ and 5′-TTT 
ATGGGGTGATGTGAGCC-3′; product size: 7,626 bp).16 
Polymerase chain reaction (PCR) amplification was performed 
using a TaKaRa LA PCR Amplification Kit (Takara Bio, Shiga, 
Japan) in a 25-μl volume containing 0.125 μl (5 units/μl) of Taq 
DNA polymerase, 2.5 μl of 10× Ex Taq buffer, 2 μl deoxynucle-
otide triphosphates (dNTPs) (2.5 mmol/l each), and 1 μmol/l 
primers. Thermal cycling was performed in a Verti thermal 
cycler (Life Technologies) with the following conditions: initial 
denaturation at 94 °C for 1 min, followed by 35 cycles at 94 °C 
for 30 s, 64 °C for 1 min, and 72 °C for 8 min, and a final exten-
sion at 72 °C for 5 min. The amplified PCR products were puri-
fied using AMPure beads (Agencourt AMPure XP; Beckman 
Coulter, Danvers, MA) and quantified using a Nanodrop-1000 
spectrophotometer (Nanodrop ND-1000; Thermo Scientific, 
Waltham, MA).
Massively Parallel Sequencing on the Ion Torrent PGM
Massively parallel sequencing was performed on the Ion 
Torrent PGM according to the manufacturer’s protocol (Life 
Technologies) and included library preparation, template prep-
aration using emulsion PCR, and PGM sequencing. Specifically, 
Ion Torrent sequencing libraries were prepared using the Ion 
Xpress Fragment Plus Library Kit (Life Technologies) accord-
ing to the manufacturer’s protocol, with purification between 
steps performed using Agencourt AMPure XP beads (Beckman 
Coulter). First, equimolar amounts of mtDNA PCR fragments 
1 and 2 were pooled for each sample and enzymatically sheared 
by incubation at 37 °C for 15 min with Ion Shear enzyme (Life 
Technologies). After adaptor ligation (using Ion Xpress bar-
codes to uniquely identify each sample), the fragments were 
size-selected (150–250 bp) using an E-Gel SizeSelect 2% aga-
rose gel (Life Technologies). The library was then amplified and 
quantified using a Qubit Fluorometer (Life Technologies). The 
library size of ~200 bp was verified using a 2100 Bioanalyzer 
(Agilent Technologies UK, Wokingham, UK). Clonal ampli-
fication of libraries on Ion Sphere particles was achieved by 
emulsion PCR performed on a One Touch system using the 
Ion OneTouch 100-bp Template Kit according to the manu-
facturer’s instructions (Life Technologies). Template-positive 
Ion Sphere particles were isolated using the Ion OneTouch ES 
enrichment system. Massively parallel sequencing was per-
formed on an Ion Torrent PGM instrument.
PGM Data Analysis
FASTQ output from the Ion Torrent was uploaded to Partek 
Flow for initial quality control and conversion to BAM files for 
analysis using Partek Genomics Suite version 6.6 (Partek, St. 
Louis, MO). The overall quality of reads was assessed using pre-
alignment quality control with 10% of reads sampled per indi-
vidual. Reads with less than 25 bases were removed and reads 
were trimmed until the quality score exceeded 20. Trimmed 
data were independently aligned using Bowtie version 0.12.7 
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(based  on default settings optimized by Partek) to NCBI 
Reference mtDNA reference sequence (revised Cambridge 
Reference Sequence) NC_012920.1, GI:251831106 (hg19) 
with 0.2-bit reference built from FASTA sequence. mtDNA 
sequences for each sample were compared with the reference 
using single-nucleotide polymorphism (SNP) and allele per-
centage options.
Sanger Sequencing of Mitochondrial Genome
To corroborate the Ion Torrent PGM massively parallel sequenc-
ing, all patient mtDNA sequences and mtDNA from ethnically 
matched controls underwent conventional Sanger sequencing. 
Nine overlapping primer pairs were used for mtDNA ampli-
fication with 62 corresponding overlapping internal sequenc-
ing primers for mtDNA sequencing as previously described.19,20 
Bidirectional cycle sequencing was performed using BigDye 
Terminator v3.1 cycle sequencing kit (Life Technologies), and 
amplified, targeted genetic regions electrophoresed on an ABI 
PRISM 3730 Genetic Analyzer (Life Technologies).
mtDNA Variant Analysis
Identified mtDNA sequence variants were compared with pub-
licly accessible databases: MITOMAP (http://www.mitomap.
org/MITOMAP), mtDB (http://www.mtdb.igp.uu.se/), dbSNP 
(Build 137) (http://www.ncbi.nlm.nih.gov/SNP/), and the 1000 
Genomes Project (http://browser.1000genomes.org/index.
html). Previously reported disease-associated sequence vari-
ants were identified using MITOMAP. Previously unreported 
or novel nucleotide changes were classified as pathogenic if they 
(i) were absent from ethnically matched controls (110 individ-
uals without glaucoma), (ii) were not reported in the 24,187 
human mitochondrial DNA sequences in MITOMAP, and (iii) 
were classified as possibly or probably damaging when con-
sidering the conservation and deleterious structural effects of 
amino acid substitutions on protein function using PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/). Identified sequence 
variants were described according to the guidelines published 
by the Human Genome Variation Society (http://www.hgvs.
org). Transitions were represented by purine–purine (A<->G) 
or pyrimidine–pyrimidine (C<->T) substitutions, and trans-
versions were represented by purine–pyrimidine substitutions 
(A<->C, A<->T, G<->C, G<->T).
RESULTS
Whole-mitochondrial genome sequencing was performed 
in 32 patients with high-tension POAG from India (n = 16) 
and Ireland (n = 16) on the Ion Torrent PGM. Pre-alignment 
quality assurance and quality control on raw reads from the 
PGM (FASTQ files) demonstrated an average read length of 98 
bases, with average quality score of 24 and 45% guanine cyto-
sine content across the sequence reads. FASTA-trimmed read 
alignments demonstrated that more than 99.98% of mtDNA 
bases were covered from an average read length of 93 bases, 
with an average depth of ×267. Unique sequence variants (n 
= 536) were identified in the Ion Torrent PGM sequencing 
data using the proportional allele model. Specifically, 334 Ion 
Torrent PGM sequence variants were confirmed by Sanger 
sequencing, whereas 57 were not confirmed by direct Sanger 
sequencing (likely false positives or below the heteroplasmy 
detection limit for Sanger sequencing), whereas the remain-
der were not able to be called by Sanger sequencing because 
of poor coverage, indels, or complex variations. Four hundred 
four unique SNPs were identified with log odds ratio >5.0 for 
the SNP-against-reference option in Partek. Eleven sequence 
variants were detected only by Sanger sequencing and were 
not identified by the algorithms used for analyzing the Ion 
Torrent PGM sequencing data (2.7% false-negative rate). 
Sequenced variants detected in ethnically matched controls 
(n = 110) were excluded from further analysis.
Sixteen of the 32 POAG patients (50% of cases) carried 
mtDNA sequence variants. We found a total of 22 mtDNA 
sequence variants, consisting of seven novel mutations and 
eight previously reported disease-associated sequence vari-
ants (Table 1); six patients (18.75%) harbored two pathogenic 
mtDNA mutations. Eight of 22 (36.4%) mtDNA mutations 
were in complex I mitochondrial genes, and five of 22 (22.7%) 
were in transfer RNAs. Among the POAG patients with muta-
tions, five of 16 (31.25%) had a mutation in the MT-ND5 gene 
in complex I. The eight previously reported disease-associated 
mtDNA sequence variants (Supplementary Table S1 online) 
were reported in MITOMAP. There was no evidence of a gen-
otype–phenotype correlation between the number or location 
of mtDNA sequence variants and the severity of the POAG 
phenotype. None of the detected mtDNA sequence variants 
has previously been reported in POAG. Ten novel synony-
mous mtDNA variants were detected (Supplementary Table 
S2 online). In the Caucasian Irish POAG patients, nine of 16 
(56.25%) had at least one pathogenic mtDNA variant, and in 
the Indian POAG patients, seven of 16 (43.75%) had at least one 
pathogenic mtDNA variant.
DISCUSSION
With a prevalence of 1–3% in Europe and up to 9% in Africa, 
glaucoma is a major cause of visual morbidity and the sec-
ond most common cause of blindness in the world, resulting 
in bilateral blindness in 4.5 million people.1,21 Visual loss with 
POAG is the result of progressive and irreversible RGC dam-
age.2 Given the high metabolic demands of RGCs, they are 
heavily dependent on mitochondrial function for their func-
tion and survival.9,22 Mitochondrial dysfunction and mtDNA 
defects have been implicated in RGC loss and the development 
of glaucoma.7,10,22,23
The expansion of massively parallel sequencing has revolu-
tionized mitochondrial genetics.24–26 Sanger sequencing has 
long been considered the gold standard for molecular diagno-
sis of mtDNA-based disorders. The vast majority of deleteri-
ous mtDNA mutations are heteroplasmic, and it is challenging 
to identify all mutations in the mitochondrial genome and 
simultaneously quantify the mtDNA heteroplasmy levels.16 
Previously, the two most popular complete mitochondrial 
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genome sequencing methods were Sanger sequencing23 and the 
Affymetrix MitoChip,27 but neither is sufficiently sensitive or 
specific to reliably detect mtDNA heteroplasmy. In compari-
son, massively parallel sequencing has been reported to detect 
mtDNA heteroplasmies of ≥5% with virtually no false-positive 
results.16,26,28 The application of massively parallel sequencing 
technology to the analysis of the mitochondrial genome has 
significantly improved the molecular diagnosis of mtDNA 
disorders.24 Large mtDNA deletions have been reported in 
mitochondrial diseases, and the ability of massively parallel 
sequencing to detect mtDNA deletions has not been firmly 
established.29 However, using an  long range PCR strategy simi-
lar to that in our study, the Ion Torrent PGM was able to detect 
two large-scale single deletions in the mtDNA of two patients.30
Two other studies have used massively parallel sequenc-
ing for whole-mitochondrial sequencing in POAG. Collins et 
al.31 used the Ion Torrent PGM to sequence the mitochondrial 
genome in 22 Afro-Caribbean POAG cases and 22 controls; 
they concluded that African-American POAG cases closely 
resembled controls with respect to frequency and types of 
mtDNA sequence variation. Using next-generation sequenc-
ing, Jeoung et al.32 identified three mtDNA SNPs (m.4883C>T 
ND2, m.9540T>C COX3, and m.14766C>T CYTB) with 
significantly different frequencies in Korean patients with 
normal-tension glaucoma as compared with controls. In the 
present study, we evaluated 32 POAG patients using massively 
parallel sequencing on the Ion Torrent PGM to investigate 
the involvement of mitochondrial genomic variants in POAG 
pathogenesis and detected pathogenic mtDNA mutations in 
50% of patients. The mutational load was consistent between 
the Irish Caucasian and Indian POAG patients, with complex I 
mitochondrial genes being the most commonly mutated, rep-
resenting 36.4% of mutations. Our study is the first to assess 
mtDNA defects in Caucasian subjects with POAG. This muta-
tional load is consistent with findings from Sanger sequencing 
of mtDNA in Middle Eastern Arabs with POAG that identified 
pathogenic mtDNA mutations in 54% of patients with POAG 
(14/27).23 Mitochondrial mutations have also been reported in 
other forms of glaucoma at low frequencies: primary congeni-
tal glaucoma (10–22.85%),33,34 primary angle closure glaucoma 
(13.8%),35 and pseudoexfoliation glaucoma (10.3%).36 All pre-
vious mtDNA sequencing studies, including our study, were 
performed on mtDNA isolated from peripheral blood leuko-
cytes, and it is known that mtDNA sequence variants may exist 
at different levels in different tissues (tissue heteroplasmy). 
Without studying mtDNA defects, including functional analy-
ses, in the target tissue within the eye, these findings cannot be 
extrapolated to the site of disease pathology; however, they do 
provide evidence that mtDNA defects are frequently present 
in leukocytes of POAG patients, indicating that mitochondrial 
dysfunction is related to disease status.
Defects in complex I oxidative phosphorylation resulting in 
decreased respiration rates and adenosine triphosphate pro-
duction have been reported in POAG lymphocytes, although 
this cohort was not screened for mtDNA defects.10 In our 
study, complex I was mutated in approximately one-third 
(31.25%) of the POAG patients with mtDNA mutations and, 
specifically, mutations in the MT-ND5 gene. Banerjee et al.37 
also observed a clustering of nonsynonymous mtDNA vari-
ants in MT-ND5 in a cohort of 101 patients with POAG from 
India evaluated by Sanger sequencing of the mitochondrial 
genome. Mitochondrial complex I is the largest component of 
the oxidative phosphorylation system and is a crucial compo-
nent of the mitochondrial respiratory chain.38,39 The function 
of complex I is essential for the maintenance of tissue reactive 
oxygen species levels, generation of mitochondrial membrane 
potential, and adenosine triphosphate production.39 Complex 
I dysfunction leads to alterations in cell survival, apoptosis, 
and calcium homeostasis, and is the most frequent respira-
tory chain defect found in neuromuscular mitochondrial 
disorders.38 Genetic dysfunction of complex I is the most 
prevalent cause of Leber hereditary optic neuropathy, an 
inherited mitochondrial optic neuropathy.40 Our study sup-
ports the emerging concept that mitochondrial dysfunction 
results in the development of glaucoma and, more specifically, 
that complex I and MT-ND5 defects play a significant role in 
POAG pathogenesis.7,22,37
Further studies using larger cohorts of glaucoma patients 
and phenotypes are required to determine the relationship 
between the mutational load in the mitochondrial genome 
and glaucoma pathogenesis. Massively parallel sequencing is 
a cost-effective approach with the high sensitivity, specificity, 
and accuracy necessary to detect a wide spectrum of mtDNA 
mutations while also quantifying levels of heteroplasmy.16,24,26,28 
Without functional correlates, distinguishing mildly patho-
genic mtDNA mutations from benign variants is challenging 
and can depend on interpretation. Future studies should corre-
late the mtDNA mutational spectrum with functional assays to 
more fully explore the role mitochondrial mutations and dys-
function play in the pathogenesis of glaucoma.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim.
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